GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (XAMS:GLPG) » Definitions » Change In Inventory

Galapagos NV (XAMS:GLPG) Change In Inventory : €0.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Change In Inventory?

Galapagos NV's change in inventory for the quarter that ended in Mar. 2025 was €0.0 Mil. It means Galapagos NV's inventory stayed the same from Dec. 2024 to Mar. 2025 .

Galapagos NV's change in inventory for the fiscal year that ended in Dec. 2024 was €23.0 Mil. It means Galapagos NV's inventory declined by €23.0 Mil from Dec. 2023 to Dec. 2024 .

Galapagos NV's Total Inventories for the quarter that ended in Mar. 2025 was €38.5 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Galapagos NV's Days Inventory for the quarter that ended in Mar. 2025 was 298.12.

Inventory Turnover measures how fast the company turns over its inventory within a year. Galapagos NV's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.31.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Galapagos NV's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.60.


Galapagos NV Change In Inventory Historical Data

The historical data trend for Galapagos NV's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Change In Inventory Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -21.17 -34.59 -24.08 23.04

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Galapagos NV Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (XAMS:GLPG) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Galapagos NV's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=44.854/13.729*365 / 4
=298.12

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Galapagos NV's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Galapagos NV's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV Change In Inventory Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

From GuruFocus

Half Year 2023 Galapagos NV Earnings Call Transcript

By GuruFocus Research 02-07-2024

FMR LLC Adjusts Stake in Galapagos NV

By GuruFocus News 11-13-2024

Galapagos NV at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-07-2024

Half Year 2024 Galapagos NV Earnings Call Transcript

By GuruFocus Research 08-03-2024

EcoR1 Capital, LLC Increases Stake in Galapagos NV

By GuruFocus News 10-08-2024

Galapagos NV at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-07-2024

Q3 2023 Galapagos NV Earnings Call Transcript

By GuruFocus Research 02-07-2024

Full Year 2023 Galapagos NV Earnings Call Transcript

By GuruFocus Research 02-28-2024